In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study

Trial Profile

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Poly ICLC (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oncovir
  • Most Recent Events

    • 24 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top